Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Pharmacogenomics of Vincristine-Induced Severe Peripheral Neuropathy in Paediatric Cancer Patients
EF 2009-10
Résumé
Vincristine is a highly effective drug that is used in the treatment of a variety of cancers, including paediatric leukemias, lymphomas, and solid tumors. However, the side effects of this drug (peripheral neuropathy and neurotoxicity) cause permanent disability issues, amongst other neurological issues. These side reactions are can be so severe that they can cause eventual loss of sensation and motor control, leading to a negative effect on their quality of life. Currently, there are no pre-screening techniques that can accurately identify the patients who are at a high risk for developing these devastating side reactions. However, the current scientific literature suggests that these side effects could be linked to inherent genetic variations between individuals, explaining why some people are affected and why others are not. It is already known that undiagnosed individuals with pre-existing peripheral neuropathy have a higher risk of exacerbating their condition. We hypothesize that there are genetic variant(s) in the metabolizing enzymes and transport systems for vincristine, and that once identified, these genetic differences will be highly predictive of susceptibility towards the side effects of vincristine.
To date, the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) has identified 143 patients with serious peripheral neuropathy and 639 drug-matched controls. As a CPNDS trainee, I will be involved in all stages of this project: from identifying the paediatric patients who received vincristine and exhibited side effects, to genotyping and analyzing for specific genetic variations. The genetic test results will be used to determine whether a relationship exists between the genes of interest and the side effects. The identification of the gene(s) that modulate the negative effects of vincristine will facilitate the development of diagnostic tools and policy changes, thereby preventing the unneeded administration of vincristine to high-risk individuals
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
201585
Name
Loo Tenneille
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Health systems / services
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Pharmacogenomics of Vincristine-Induced Severe Peripheral Neuropathy in Paediatric Cancer Patients
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Reactions (Side Effects); Drug Interactions; Drug Safety Policies (Health Policy); Epidemiology; Genetics; Literature Studies; Pharmacogenetics; Pharmacology; Population Health; Statistical Analysis
Abstract
Vincristine is a highly effective drug that is used in the treatment of a variety of cancers, including paediatric leukemias, lymphomas, and solid tumors. However, the side effects of this drug (peripheral neuropathy and neurotoxicity) cause permanent disability issues, amongst other neurological issues. These side reactions are can be so severe that they can cause eventual loss of sensation and motor control, leading to a negative effect on their quality of life. Currently, there are no pre-screening techniques that can accurately identify the patients who are at a high risk for developing these devastating side reactions. However, the current scientific literature suggests that these side effects could be linked to inherent genetic variations between individuals, explaining why some people are affected and why others are not. It is already known that undiagnosed individuals with pre-existing peripheral neuropathy have a higher risk of exacerbating their condition. We hypothesize that there are genetic variant(s) in the metabolizing enzymes and transport systems for vincristine, and that once identified, these genetic differences will be highly predictive of susceptibility towards the side effects of vincristine.
To date, the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) has identified 143 patients with serious peripheral neuropathy and 639 drug-matched controls. As a CPNDS trainee, I will be involved in all stages of this project: from identifying the paediatric patients who received vincristine and exhibited side effects, to genotyping and analyzing for specific genetic variations. The genetic test results will be used to determine whether a relationship exists between the genes of interest and the side effects. The identification of the gene(s) that modulate the negative effects of vincristine will facilitate the development of diagnostic tools and policy changes, thereby preventing the unneeded administration of vincristine to high-risk individuals
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Loo, Tenneille
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~